Actuate Therapeutics, Inc. Common stock Working Capital to Net Assets Ratio

Latest as of September 2025: 101.2%

Actuate Therapeutics, Inc. Common stock working capital to net assets ratio. Actuate Therapeutics, Inc. Common stock (ACTU) has a Working Capital to Net Assets ratio of 101.2% as of September 2025. Working capital of $11.07 Million (current assets of $17.44 Million minus current liabilities of $6.37 Million) is measured against net assets of $10.94 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Actuate Therapeutics, Inc. Common stock (ACTU) tangible net worth to evaluate the tangible quality of the company's equity base.

WC/NA Ratio

101.2%
Working Capital / Net Assets

Working Capital

$11.07 Million
USD

Current Assets

$17.44 Million
USD

Current Liabilities

$6.37 Million
USD

Working Capital to Net Assets Ratio of Actuate Therapeutics, Inc. Common stock (2022–2024)

Working capital to net assets ratio of Actuate Therapeutics, Inc. Common stock from 2022 to 2024. This chart shows how Actuate Therapeutics, Inc. Common stock's Working Capital to Net Assets ratio has evolved across 3 annual periods from 2022 to 2024. As of September 2025, the ratio stands at 101.2%, reflecting working capital of $11.07 Million against net assets of $10.94 Million USD. Read total liabilities of Actuate Therapeutics, Inc. Common stock for a breakdown of total debt and financial obligations.

Actuate Therapeutics, Inc. Common stock Working Capital to Net Assets Ratio by Year (2022–2024)

Actuate Therapeutics, Inc. Common stock working capital to net assets ratio by year from 2022 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Actuate Therapeutics, Inc. Common stock from 2022 to 2024, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Actuate Therapeutics, Inc. Common stock.

Year WC/NA Ratio Working Capital (USD) Net Assets Current Assets Current Liabilities Change (pp)
2024 389.1% $405.40K $104.19K $9.21 Million $8.80 Million ▲ +385.2 pp
2023 3.9% $-3.93 Million $-99.63 Million $3.00 Million $6.92 Million ▼ -104.9 pp
2022 108.8% $16.14 Million $14.83 Million $20.48 Million $4.34 Million —
pp = percentage points